首页> 外文期刊>EBioMedicine >The clinical potential of IL-12/IL-35 in treating chemotherapy drug-induced cardiac injury – Authors' reply
【24h】

The clinical potential of IL-12/IL-35 in treating chemotherapy drug-induced cardiac injury – Authors' reply

机译:IL-12 / IL-35在治疗化疗药物性心脏损伤中的临床潜力–作者的回复

获取原文
           

摘要

Doxorubicin (DOX) is an important chemotherapy drug that can beused in a variety of chemotherapy regimens for cancer patients, but itcan lead to serious clinical complications, especially heart damage.In our recent paper, we found that deletion of interleukin (IL)-12p35(deletion of the shared subunits of IL-12 and IL-35) aggravated DOXinducedcardiac injury and deteriorated cardiac function, while supplementationwith exogenous IL-12/IL-35 significantly attenuated thecardiac injury [1]. In his commentary on our paper, Dr. Jia exhibited profoundunderstanding of the role of chemotherapy drugs in myocardialinjury, systematically summarized our articles and pointed out sometrue shortcomings. Dr. Jia also suggested that IL-12/IL-35 has potentialclinical value for the treatment of cardiac injury induced by clinical chemotherapydrugs [2]. In summary, we thank Dr. Jia for his professionalcomments and completely agree that the limitations he raised do existin our paper. Now, we simply respond to the prospect that IL-12/IL-35could protect against chemotherapy-induced cardiac injury in the clinic.
机译:阿霉素(DOX)是一种重要的化学治疗药物,可用于癌症患者的多种化学治疗方案,但会导致严重的临床并发症,尤其是心脏损害。在我们最近的论文中,我们发现白介素(IL)-12p35的缺失(删除IL-12和IL-35的共有亚基)加重了DOX诱发的心脏损伤并恶化了心功能,而补充外源性IL-12 / IL-35则明显减轻了心脏损伤[1]。贾博士在对我们论文的评论中,对化疗药物在心肌损伤中的作用表现出了深刻的理解,系统地总结了我们的文章并指出了一些真正的缺点。贾博士还建议IL-12 / IL-35在临床化学药物诱发的心脏损伤治疗中具有潜在的临床价值[2]。总之,我们感谢贾博士的专业评论,并完全同意他提出的限制确实存在于我们的论文中。现在,我们简单地回应了IL-12 / IL-35可以在临床中预防化疗引起的心脏损伤的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号